Across the past 12 months, open-market trades by Viking Therapeutics insiders totaled $149,912 in purchases (4.47K shares) and $22.25 million in sales (664.04K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Brian Lian | President Ceo | 2,572,441 | 0 | 2,572,441 | 74.5% | 29 Jul, 2026 |
| 2 | Marianna Mancini | Chief Operating Officer | 422,760 | 0 | 422,760 | 12.2% | 29 Jul, 2026 |
| 3 | Greg Zante | Chief Financial Officer | 212,204 | 0 | 212,204 | 6.1% | 29 Jul, 2026 |
| 4 | Matthew W Foehr | Director | 135,186 | 0 | 135,186 | 3.9% | 05 Jan, 2026 |
| 5 | Lawson Macartney | Director | 51,115 | 0 | 51,115 | 1.5% | 05 Jan, 2026 |
| 6 | Charles A Jr Rowland | Director | 33,150 | 0 | 33,150 | 1.0% | 05 Jan, 2026 |
| 7 | J Matthew Singleton | Director | 12,650 | 0 | 12,650 | 0.4% | 05 Jan, 2026 |
| 8 | Dorothy Elizabeth Kelly-Gemmell | Director | 6,333 | 0 | 6,333 | 0.2% | 07 Aug, 2026 |
| 9 | Neil William Aubuchon | Chief Commercial Officer | 4,475 | 0 | 4,475 | 0.1% | 10 Mar, 2026 |
| 10 | Sarah Kathryn Rouan | Director | 4,390 | 0 | 4,390 | 0.1% | 05 Jan, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 01 Aug, 2026 | Dorothy Elizabeth Kelly-Gemmell | Director | Acquired A | 6,333 | $0.00 | $0 | 6,333 | Direct |
| 01 Aug, 2026 | Dorothy Elizabeth Kelly-Gemmell | Director | Acquired A | 40,800 | $0.00 | $0 | 40,800 | Direct |
| 28 Jul, 2026 | Greg Zante | Chief Financial Officer | Acquired A | 31,667 | $0.00 | $0 | 233,421 | Direct |
| 28 Jul, 2026 | Marianna Mancini | Chief Operating Officer | Acquired A | 31,667 | $0.00 | $0 | 440,977 | Direct |
| 28 Jul, 2026 | Brian Lian | President Ceo | Acquired A | 221,667 | $0.00 | $0 | 2,720,958 | Direct |
| 29 Jul, 2026 | Brian Lian | President Ceo | Disposed S | 148,517 | $33.32 | $4.95Mn | 2,572,441 | Direct |
| 29 Jul, 2026 | Greg Zante | Chief Financial Officer | Disposed S | 21,217 | $33.47 | $710.14K | 212,204 | Direct |
| 29 Jul, 2026 | Marianna Mancini | Chief Operating Officer | Disposed S | 18,217 | $33.47 | $609.64K | 422,760 | Direct |
| 01 Jun, 2026 | Hubert C Chen | Chief Medical Officer | Acquired A | 190,000 | $0.00 | $0 | 190,000 | Direct |
| 10 Mar, 2026 | Neil William Aubuchon | Chief Commercial Officer | Acquired P | 4,475 | $33.50 | $149.91K | 4,475 | Direct |
| 12 Jan, 2026 | Neil William Aubuchon | Chief Commercial Officer | Acquired A | 180,000 | $0.00 | $0 | 180,000 | Direct |
| 02 Jan, 2026 | Sarah Kathryn Rouan | Director | Acquired A | 3,150 | $0.00 | $0 | 4,390 | Direct |
| 02 Jan, 2026 | Marianna Mancini | Chief Operating Officer | Acquired A | 41,000 | $0.00 | $0 | 434,802 | Direct |
| 02 Jan, 2026 | Lawson Macartney | Director | Acquired A | 3,150 | $0.00 | $0 | 51,115 | Direct |
| 02 Jan, 2026 | Greg Zante | Chief Financial Officer | Acquired A | 41,000 | $0.00 | $0 | 215,483 | Direct |
| 02 Jan, 2026 | Charles A Jr Rowland | Director | Acquired A | 3,150 | $0.00 | $0 | 33,150 | Direct |
| 02 Jan, 2026 | J Matthew Singleton | Director | Acquired A | 3,150 | $0.00 | $0 | 12,650 | Direct |
| 02 Jan, 2026 | Matthew W Foehr | Director | Acquired M | 16,000 | $3.33 | $53.28K | 148,036 | Direct |
| 02 Jan, 2026 | Brian Lian | President Ceo | Acquired A | 78,400 | $0.00 | $0 | 2,508,620 | Direct |
| 02 Jan, 2026 | Matthew W Foehr | Director | Disposed S | 16,000 | $35.11 | $561.69K | 132,036 | Direct |